Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Evgen Pharma, a clinical stage drug development company, announced its support for a new research collaboration between King's College London and the British Heart Foundation investigating how the company's breast cancer drug can enhance neurovascular protection.
'Evgen will supply SFX-01 to the project and has the right to negotiate a licence over any resultant intellectual property, on fair and reasonable preferential terms,' the company said. 'If successful, the research will provide further insight into how SFX-01 mediates upregulation of Nrf2 in the blood-brain barrier endothelium, thereby enhancing neurovascular protection.'
This work will build on the existing collaboration between Evgen and King's. The collaboration had shown 'great promise for SFX-01 in both stroke and potentially wider neuropsychiatric complication,' Evgen added,
At 8:00am: (LON:EVG) Evgen Pharma Plc share price was 0p at 17.88p